دورية أكاديمية
Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine.
| العنوان: | Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine. |
|---|---|
| المؤلفون: | Wang Z; School of Pharmacy Lanzhou University, Lanzhou, Gansu, China., Gao Y; School of Pharmacy Lanzhou University, Lanzhou, Gansu, China., Ji X; School of Pharmacy Lanzhou University, Lanzhou, Gansu, China., Wu T; School of Pharmacy Lanzhou University, Lanzhou, Gansu, China., Pu L; School of Pharmacy Lanzhou University, Lanzhou, Gansu, China., Qiu W; National Drug Clinical Trial Institution, Lanzhou University Second Hospital, Lanzhou, Gansu, China.; Pharmacy Department, Lanzhou University Second Hospital, Lanzhou, Gansu, China. |
| المصدر: | Journal of clinical pharmacology [J Clin Pharmacol] 2024 May; Vol. 64 (5), pp. 601-608. Date of Electronic Publication: 2024 Jan 04. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2013- : Oxford : Wiley Original Publication: Stamford, Conn., Hall Associates. |
| مواضيع طبية MeSH: | Cytochrome P-450 CYP2D6*/genetics , Cytochrome P-450 CYP2D6*/metabolism , Benzylamines*/pharmacokinetics , Benzylamines*/administration & dosage , Benzylamines*/blood , Naphthalenes*/pharmacokinetics , Naphthalenes*/administration & dosage , Selective Serotonin Reuptake Inhibitors*/pharmacokinetics , Selective Serotonin Reuptake Inhibitors*/blood , Selective Serotonin Reuptake Inhibitors*/administration & dosage , Asian People*/genetics , Genotype*, Humans ; Male ; Adult ; Young Adult ; Polymorphism, Genetic ; Area Under Curve ; Healthy Volunteers ; East Asian People |
| مستخلص: | Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) used to treat premature ejaculation (PE), and is mainly metabolized by CYP2D6, CYP3A4, and flavin-containing monooxygenase 1. The purpose of the study was to evaluate the effect of CYP2D6 polymorphism on the pharmacokinetics of dapoxetine in healthy Chinese men. Thirty-nine subjects who received a single oral dose of 30 mg dapoxetine hydrochloride were classified based on their CYP2D6 genotype: *1/*1 (n = 9), *1/*41 (n = 1), *1/*10 (n = 12), *10/*41 (n = 3), or *10/*10 (n = 14). The difference in pharmacokinetic parameters between different genotype groups was analyzed and then scored according to the activity score system. Compared with the wild-type subjects of CYP2D6 *1/*1, the peak plasma concentration (C (© 2023, The American College of Clinical Pharmacology.) |
| References: | Crowdis M, Leslie SW, Nazir S. Premature Ejaculation. StatPearls; 2023. Brock GB, Benard F, Casey R, Elliott SL, Gajewski JB, Lee JC. Canadian male sexual health council survey to assess prevalence and treatment of premature ejaculation in Canada. J Sex Med. 2009;6(8):2115‐2123. doi:10.1111/j.1743‐6109.2009.01362.x. Rosen RC, Althof S. Impact of premature ejaculation: the psychological, quality of life, and sexual relationship consequences. J Sex Med. 2008;5(6):1296‐1307. doi:10.1111/j.1743‐6109.2008.00825.x. Rowland DL, Patrick DL, Rothman M, Gagnon DD. The psychological burden of premature ejaculation. J Urol. 2007;177(3):1065‐1070. doi:10.1016/j.juro.2006.10.025. Wu PC, Hung CS, Kang YN, Wu CC. Tolerability and optimal therapeutic dosage of clomipramine for premature ejaculation: a systematic review and meta‐analysis. Sex Med. 2021;9(1):100283. doi:10.1016/j.esxm.2020.10.011. Zhang H, Colonnello E, Sansone A, et al. Acupuncture for premature ejaculation: a systematic review and meta‐analysis. Sex Med. 2023;11(3):qfad034. doi:10.1093/sexmed/qfad034. Waldinger MD. Pharmacotherapy for premature ejaculation. Curr Opin Psychiatry. 2014;27(6):400‐405. doi:10.1097/YCO.0000000000000096. FDA. Dietary Supplement Ingredient Directory. Updated 07/12/2023. https://www.fda.gov/food/dietary‐supplements/dietary‐supplement‐ingredient‐directory. FDA. Public Notification: One More Knight 1750 contains hidden drug ingredients. Updated 02/21/2018. https://www.fda.gov/drugs/medication‐health‐fraud/public‐notification‐one‐more‐knight‐1750‐contains‐hidden‐drug‐ingredients. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open. 2018;1(6):e183337. doi:10.1001/jamanetworkopen.2018.3337. White CM. Continued risk of dietary supplements adulterated with approved and unapproved drugs: assessment of the US Food and Drug Administration's Tainted Supplements Database 2007 through 2021. J Clin Pharmacol. 2022;62(8):928‐934. doi:10.1002/jcph.2046. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804‐814. doi:10.1016/j.eururo.2010.02.020. Zhao GJ, Guo Q, Li YF, Zhang YG. Efficacy and safety of dapoxetine for premature ejaculation: an updated systematic review and meta‐analysis. Sex Health. 2019;16(4):301‐313. doi:10.1071/SH18005. Liu J, Li Z, Yan K, Ju G, Qiu W. Pharmacokinetics and safety of dapoxetine hydrochloride in healthy Chinese men: impact of dose and high‐fat meal. Clin Pharmacol Drug Dev. 2021;10(10):1216‐1224. doi:10.1002/cpdd.919. Meloche M, Khazaka M, Kassem I, Barhdadi A, Dube MP, de Denus S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta‐analysis. Br J Clin Pharmacol. 2020;86(6):1015‐1033. doi:10.1111/bcp.14247. Waade RB, Solhaug V, Hoiseth G. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. Br J Clin Pharmacol. 2021;87(5):2228‐2235. doi:10.1111/bcp.14626. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215‐223. doi:10.1038/gim.2016.87. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376‐382. doi:10.1038/clpt.2013.254. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127‐134. doi:10.1002/cpt.147. Koopmans AB, Braakman MH, Vinkers DJ, Hoek HW, van Harten PN. Meta‐analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry. 2021;11(1):141. doi:10.1038/s41398‐020‐01129‐1. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83(2):234‐242. doi:10.1038/sj.clpt.6100406. Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110(4):888‐896. doi:10.1002/cpt.2149. Caudle KE, Sangkuhl K, Whirl‐Carrillo M, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116‐124. doi:10.1111/cts.12692. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single‐ and multiple‐dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. 2006;46(3):301‐309. doi:10.1177/0091270005284850. Frederiksen T, Areberg J, Schmidt E, Bjerregaard Stage T, Brosen K. Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through population pharmacokinetic analysis of vortioxetine. Clin Pharmacol Ther. 2021;109(1):150‐159. doi:10.1002/cpt.1972. Kringen MK, Braten LS, Haslemo T, Molden E. The influence of combined CYP2D6 and CYP2C19 genotypes on venlafaxine and O‐desmethylvenlafaxine concentrations in a large patient cohort. J Clin Psychopharmacol. 2020;40(2):137‐144. doi:10.1097/JCP.0000000000001174. Zastrozhin M, Skryabin V, Petukhov A, et al. Effects of CYP2D6*4 polymorphism on the steady‐state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder. J Psychopharmacol. 2022;36(10):1146‐1150. doi:10.1177/02698811221112939. Xu RA, Gu EM, Zhou Q, et al. Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine. Drug Des Devel Ther. 2016;10:687‐696. doi:10.2147/DDDT.S97789. Tang S, Zhao P, Zheng L, Wen C, Wang L, Jiang X. Impacts of cytochrome P450 2D6*10 allele and a high‐fat meal on the pharmacokinetics of dapoxetine in healthy Chinese men: a single‐dose, two‐treatment study. Adv Ther. 2019;36(8):2096‐2105. doi:10.1007/s12325‐019‐00982‐x. Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A. (Vice‐chair). EAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism. u2018. SRL AMFI. Priligy 30 mg film‐coated tablets. Updated 09/28/2021. https://www.medicines.org.uk/emc/product/1269/smpc. Garcia‐Barcelo M, Chow LY, Chiu HF, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem. 2000;46(1):18‐23. Ismail Al‐Khalil W, Al‐Salhi L, Rijjal S, Aljamali M, Youssef LA. The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. BMC Cancer. 2022;22(1):1067. doi:10.1186/s12885‐022‐10148‐8. Chen R, Wang H, Shi J, Shen K, Hu P. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled‐release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. Eur J Clin Pharmacol. 2015;71(7):835‐841. doi:10.1007/s00228‐015‐1855‐6. Bae JW, Oh KY, Yoon SJ, et al. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res. 2020;43(11):1207‐1213. doi:10.1007/s12272‐020‐01293‐4. Nofziger C, Turner AJ, Sangkuhl K, et al. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020;107(1):154‐170. doi:10.1002/cpt.1643. Dorji PW, Tshering G, Na‐Bangchang K. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South‐East and East Asian populations: a systematic review. J Clin Pharm Ther. 2019;44(4):508‐524. doi:10.1111/jcpt.12835. Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther. 2023;114(1):51‐68. doi:10.1002/cpt.2903. Mondaini N, Fusco F, Cai T, Benemei S, Mirone V, Bartoletti R. Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a “Waterloo”. Urology. 2013;82(3):620‐624. doi:10.1016/j.urology.2013.05.018. Administration AGDoHaATG. Australian Public Assessment Report for Dapoxetine. 2010:40. Accessed August 27, 2010. https://www.tga.gov.au/sites/default/files/auspar‐priligy.pdf. |
| فهرسة مساهمة: | Keywords: CYP2D6 *10; CYP2D6 *41; activity score; dapoxetine; pharmacokinetics; premature ejaculation |
| المشرفين على المادة: | GB2433A4M3 (dapoxetine) EC 1.14.14.1 (Cytochrome P-450 CYP2D6) 0 (Benzylamines) 0 (Naphthalenes) 0 (Selective Serotonin Reuptake Inhibitors) |
| تواريخ الأحداث: | Date Created: 20231207 Date Completed: 20240424 Latest Revision: 20240508 |
| رمز التحديث: | 20240509 |
| DOI: | 10.1002/jcph.2391 |
| PMID: | 38059315 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!